

Oregon Health & Science University Hospital and Clinics Provider's Orders



ADULT AMBULATORY INFUSION ORDER
Eptinezumab-jjmr
(VYEPTI) Infusion

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

Page 1 of 2

Patient Identification

This plan will expire after 365 days at which time a new order will need to be placed

GUIDELINES FOR ORDERING

- 1. Send FACE SHEET and H&P or most recent chart note.
- 2. The recommended initial dose is 100 mg administered by intravenous infusion every 3 months. Some patients may benefit from a dosage of 300 mg administered by intravenous infusion every 3 months.

NURSING ORDERS:

1. Monitor patient for hypersensitivity reaction, including anaphylaxis, for 30 minutes after eptinezumabjmmr administration.

MEDICATIONS:

eptinezumab-jmmr (VYEPTI) in sodium chloride 0.9%, 100 mL, ONCE, over 30 minutes

Dose: (must select one)

□ 100 mg □ 300 mg

Interval: Every 3 months

HYPERSENSITIVITY MEDICATIONS:

- 1. NURSING COMMUNICATION If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (OHSU HC-PAT-133-GUD, HMC C-132). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.
- 2. diphenhydrAMINE (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 3. EPINEPHrine HCI (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 5. famotidine (PEPCID) injection, 20 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction



Oregon Health & Science University Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER

Eptinezumab-jjmr (VYEPTI) Infusion

ACCOUNT NO. MED. REC. NO. NAME BIRTHDATE

Page 2 of 2

Patient Identification

ALL ORDERS MUST BE MARK	ED IN INK WITH A CHECKMAN	K(*) TO BE ACTIVE.		
By signing below, I represent the following: I am responsible for the care of the patient (who I hold an active, unrestricted license to practice that corresponds with state where you provide state if not Oregon);	o is identified at the top of emedicine in: ☐ Oregon care to patient and where	u (check be you are currently licensed. Specific	эх fy	
My physician license Number is # PRESCRIPTION); and I am acting within my so	cope of practice and author	orized by law to order Infusion of the	he	
medication described above for the patient ider	ntified on this form.	·		
Provider signature:	Date/T	Date/Time:		
Printed Name:	Phone:	Fax:		
<u>Central Intake:</u> Phone: 971-262-9645 (providers only) Fax: 503 Please check the appropriate box for the pa		ocation:		
□ Beaverton OHSU Knight Cancer Institute 15700 SW Greystone Court Beaverton, OR 97006 Phone number: 971-262-9000 Fax number: 503-346-8058	NW Portland Legacy Good Medical Office 1130 NW 22nd Portland, OR 9	NW Portland Legacy Good Samaritan campus Medical Office Building 3, Suite 150 1130 NW 22nd Ave Portland, OR 97210 Phone number: 971-262-9600 Fax number: 503-346-8058		
☐ Gresham Legacy Mount Hood campus Medical Office Building 3, Suite 140 24988 SE Stark Gresham, OR 97030 Phone number: 971-262-9500 Fax number: 503-346-8058	Medical Office 19260 SW 65t Tualatin, OR 9	7062 <mark>r: 971-262-9700</mark>		

Infusion orders located at: www.ohsuknight.com/infusionorders